twitter.com/neuralink/statu...
"We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!
This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people.
Recruitment is not yet open for our clinical trial. We’ll announce more information on this soon!"
The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study
Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients 
Trials coming from Zhittya 
Clinical Stabilization in Parkinson´s Disease: The Multi-Target Treatment Description and Results
